Madhu Natarajan, Takeda rare disease development head

Drawn to the idea of turn­ing B cells in­to 'pro­tein fac­to­ries,' Take­da jumps in­to a mile­stone-heavy, $900M pact

Mad­hu Natara­jan can trace his fas­ci­na­tion with the idea of tak­ing B cells and turn­ing them in­to pro­tein fac­to­ries back 20 years, when he had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.